Article
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Neuro-oncology - 1 Sept 2021
Tesileanu C Mircea S, van den Bent Martin J, Sanson Marc, Wick Wolfgang, Brandes Alba A, Clement Paul M, Erridge Sara C, Vogelbaum Michael A, Nowak Anna K, Baurain Jean F, Mason Warren P, Wheeler Helen, Chinot Olivier L, Gill Sanjeev, Griffin Matthew, Rogers Leland, Taal Walter, Rudà Roberta, Weller Michael, McBain Catherine, van Linde Myra E, Sabedot Thais S, Hoogstrate Youri, von Deimling Andreas, de Heer Iris, van IJcken Wilfred F J, Brouwer Rutger W W, Aldape Kenneth, Jenkins Robert B, Dubbink Hendrikus J, Kros Johan M, Wesseling Pieter, Cheung Kin Jip, Golfinopoulos Vassilis, Baumert Brigitta G, Gorlia Thierry, Noushmehr Houtan, French Pim J
Abstract excerpt
BACKGROUND: Survival in patients with IDH1/2-mutant (mt) anaplastic astrocytomas is highly variable. We have used the prospective phase 3 CATNON trial to identify molecular factors related to outcome in IDH1/2mt anaplastic astrocytoma patients. METHODS: The CATNON trial randomized 751 adult patients with newly diagnosed 1p/19q non-codeleted anaplastic glioma to 59.4 Gy radiotherapy +/- concurrent and/or adjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.